دورية أكاديمية

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

التفاصيل البيبلوغرافية
العنوان: Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
المؤلفون: de Bono, Johann S *, Mehra, Niven, Scagliotti, Giorgio V, Castro, Elena, Dorff, Tanya, Stirling, Adam, Stenzl, Arnulf, Fleming, Mark T, Higano, Celestia S, Saad, Fred, Buttigliero, Consuelo, van Oort, Inge M, Laird, A Douglas, Mata, Marielena, Chen, Hsiang-Chun, Healy, Cynthia G, Czibere, Akos, Fizazi, Karim
المصدر: In The Lancet Oncology September 2021 22(9):1250-1264
قاعدة البيانات: ScienceDirect
الوصف
تدمد:14702045
DOI:10.1016/S1470-2045(21)00376-4